A systematic review of six small trials found psilocybin was associated with reduced depression scores, but evidence remains preliminary and the review is not yet peer-reviewed.
⚠️ Not peer-reviewed. This is a preprint — findings may change before publication.
Evidence grade A · meta-analysis / systematic review. Here’s an honest read of what this study does — and doesn’t — show.
Original art — ShroomWire
What the study found
Researchers found that psilocybin was associated with lower depressive scores in adults with treatment-resistant depression across six trials. Common adverse events included anxiety, nausea, headache, fatigue, and suicidal ideation, though no serious safety concerns or physiological toxicity were identified. The review noted limitations including small sample sizes, open-label designs, and heterogeneous psychotherapy protocols across studies.
Why it matters
The review synthesizes emerging research on a novel approach for patients who have not responded to conventional treatments, though it emphasizes that larger, methodologically robust randomized trials are needed before conclusions can be drawn. Note: this is a preprint and has not yet undergone peer review.
This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
Frequently asked questions
Is psilocybin safe for people with treatment-resistant depression?
The review found no serious safety concerns or physiological toxicity, though common adverse events included anxiety, nausea, headache, fatigue, and suicidal ideation. However, this is not medical advice—anyone considering psilocybin should consult a qualified professional.
Does psilocybin cure depression?
No. The review found psilocybin was associated with reduced depression scores, but it cannot establish that psilocybin causes this effect due to methodological limitations like open-label designs and lack of blinding. Evidence remains preliminary.
What are the main limitations of the psilocybin depression research?
The included trials had small sample sizes, open-label designs, heterogeneous psychotherapy protocols, and lack of blinding—all of which may bias results. The review itself is also a preprint and has not yet been peer-reviewed.
Can psilocybin replace standard antidepressants?
The review cannot determine this. There is insufficient data to compare psilocybin directly to standard antidepressants or to establish optimal dosing. Larger, methodologically robust randomized trials are needed before any conclusions can be drawn.
Imagine stepping into a sensory deprivation tank, and within minutes, your brain waves slow, and your mind enters a deep state of relaxation, comparable…
What if the key to healing trauma, depression, and existential despair lies not in pills, but in the subconscious? A groundbreaking review reveals how…
A randomized trial gave healthy adults LSD or placebo, then tested their learning the next day — here’s what the brain-plasticity data actually showed.
Psilocybin therapy was associated with significant depression remission, but may suggest unpredictable outcomes for vulnerable individuals due to serious…
DMT therapy was associated with a significant reduction in substance misuse, but may require skilled counseling and longer integration periods to be effective
